| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6194215 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
Racial disparities in the receipt of definitive therapy for high-risk prostate cancer are greatest in low-income communities, suggesting that interventions to reduce racial disparities should target low-income populations first.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
David R. B.S., Brandon A. B.S., Ayal A. M.D., M.H.S., Andrew S. B.A., Clair J. M.D., Anthony V. M.D., Ph.D., Toni K. M.D., Aymen M.D., M.A., M.P.H., Christopher S. M.D., M.S., M.P.H., Neil E. M.D., M.P.H., Christopher J. M.B.B.S., Quoc-Dien M.D.,